- Home
- MHLD vs PEPG Comparison
MHLD vs PEPG Comparison
Compare MHLD & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MHLD
- PEPG
- Stock Information
- Founded
- MHLD 2007
- PEPG 2018
- Country
- MHLD Bermuda
- PEPG United States
- Employees
- MHLD N/A
- PEPG N/A
- Industry
- MHLD Property-Casualty Insurers
- PEPG Biotechnology: Pharmaceutical Preparations
- Sector
- MHLD Finance
- PEPG Health Care
- Exchange
- MHLD Nasdaq
- PEPG Nasdaq
- Market Cap
- MHLD 159.6M
- PEPG 147.0M
- IPO Year
- MHLD 2008
- PEPG 2022
- Fundamental
- Price
- MHLD $1.35
- PEPG $4.30
- Analyst Decision
- MHLD
- PEPG Buy
- Analyst Count
- MHLD 0
- PEPG 3
- Target Price
- MHLD N/A
- PEPG $14.67
- AVG Volume (30 Days)
- MHLD 114.6K
- PEPG 215.7K
- Earning Date
- MHLD 11-12-2024
- PEPG 11-07-2024
- Dividend Yield
- MHLD N/A
- PEPG N/A
- EPS Growth
- MHLD N/A
- PEPG N/A
- EPS
- MHLD N/A
- PEPG N/A
- Revenue
- MHLD $89,074,000.00
- PEPG N/A
- Revenue This Year
- MHLD N/A
- PEPG N/A
- Revenue Next Year
- MHLD N/A
- PEPG N/A
- P/E Ratio
- MHLD N/A
- PEPG N/A
- Revenue Growth
- MHLD 20.80
- PEPG N/A
- 52 Week Low
- MHLD $1.19
- PEPG $2.90
- 52 Week High
- MHLD $2.52
- PEPG $19.30
- Technical
- Relative Strength Index (RSI)
- MHLD 37.38
- PEPG 33.61
- Support Level
- MHLD $1.32
- PEPG $2.90
- Resistance Level
- MHLD $1.42
- PEPG $5.72
- Average True Range (ATR)
- MHLD 0.10
- PEPG 0.79
- MACD
- MHLD -0.02
- PEPG -0.01
- Stochastic Oscillator
- MHLD 9.09
- PEPG 35.44
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.
About PEPG PepGen Inc.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.